Michael Schleuning
Overview
Explore the profile of Michael Schleuning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
833
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Weisser M, Schleuning M, Haferlach C, Schwerdtfeger R, Kolb H
Leuk Lymphoma
. 2007 Feb;
48(2):295-301.
PMID: 17325889
To determine the impact of imatinib therapy prior to allogeneic stem-cell transplantation in advanced stage chronic myelogenous leukaemia (CML), 30 CML patients who had received imatinib as part of pre-transplant...
12.
Deininger M, Schleuning M, Greinix H, Sayer H, Fischer T, Martinez J, et al.
Haematologica
. 2006 Apr;
91(4):452-9.
PMID: 16585011
Background And Objectives: Imatinib is an effective treatment for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). However, relapse is common in patients with advanced or...
13.
Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, et al.
Blood
. 2006 Mar;
108(3):1092-9.
PMID: 16551971
A sequential regimen of chemotherapy, reduced-intensity conditioning (RIC) for allogeneic stem cell transplantation (SCT), and prophylactic donor lymphocyte transfusion (pDLT) was studied in 103 patients with refractory acute myeloid leukemia...
14.
Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H
J Clin Oncol
. 2005 Aug;
23(24):5675-87.
PMID: 16110027
Purpose: To improve the effect of allogeneic stem-cell transplantation by sequential use of intensive chemotherapy, reduced-intensity conditioning (RIC), and prophylactic donor lymphocyte transfusions (pDLTs) in high-risk acute myeloid leukemia (AML)...
15.
Hentrich M, Oruzio D, Jager G, Schlemmer M, Schleuning M, Schiel X, et al.
Br J Haematol
. 2004 Dec;
128(1):66-72.
PMID: 15606551
We studied 228 consecutive stem cell transplant recipients, screened for reactivation of human herpesvirus-6 (HHV-6) in peripheral blood and other specimens as clinically indicated by means of qualitative polymerase chain...
16.
Schleuning M, Buxbaum-Conradi H, Jager G, Kolb H
Hematol J
. 2004 Mar;
5(2):135-44.
PMID: 15048064
In a retrospective analysis, we identified 38 evaluable patients who received intravenous ribavirin after adenovirus or RSV detection in the respiratory and/or gastrointestinal tract throughout the years 1998 and 2001....
17.
Kolb H, Schmid C, Chen X, Woiciechowski A, Roskrow M, Weber M, et al.
Acta Haematol
. 2003 Oct;
110(2-3):110-20.
PMID: 14583671
Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect of allogeneic marrow transplantation has long been known, but only recently have...
18.
Kolb H, Guenther W, Gyurkocza B, Hoetzl F, Simoes B, Falk C, et al.
Transplantation
. 2003 Jun;
75(9 Suppl):26S-31S.
PMID: 12819487
Stem-cell transplantation from human leukocyte antigen (HLA)-haploidentical family members carries a high risk of rejection and graft-versus-host disease (GVHD) if donor and recipient differ by more than one HLA antigen....
19.
Schleuning M, Stoetzer O, Waterhouse C, Schlemmer M, Ledderose G, Kolb H
Exp Hematol
. 2002 Feb;
30(1):7-10.
PMID: 11823031
Objective: Sickle cell disease generates considerable morbidity and mortality. Allogeneic hematopoietic stem cell transplantation (SCT) has the potential of curing the disease and halting end-organ damage. However, in older patients...